

Amendments to the Claims

Please amend claims as shown below in the List of Claims.

List of Claims

- 1-4. Cancelled.
5. (Currently amended) A pharmaceutical composition in unit dosage form suitable for oral administration to a human for the treatment of migraine headache, comprising: metoclopramide and naproxen, present in an amount such that the combination is effective in reducing or eliminating pain associated with said migraine headache and wherein said dosage form is an acid-base storage stabilized ~~dosage form~~ due to either:
 - a) a barrier coating separating said metoclopramide from said naproxen; or
 - b) said naproxen and said metoclopramide being segregated into separate layers of a multilayer dosage form.
6. (Previously presented) A pharmaceutical composition in unit dosage form suitable for oral administration to a human for the treatment of migraine headache, comprising: metoclopramide and an analgesic, present in an amount such that the combination is effective in reducing or eliminating pain associated with said migraine headache and wherein said dosage form is coordinated.
7. (Previously presented) The pharmaceutical composition of claim 6, wherein said unit dosage form is a tablet or capsule.
8. (Previously presented) The pharmaceutical composition of claim 7, wherein said metoclopramide and said analgesic are in separate layers of a multilayer tablet.
9. (Previously presented) The pharmaceutical composition of claim 6, wherein said unit dosage form is substantially free from any 5 HT agonist vasoactive agent.

10. (Previously presented) The pharmaceutical composition of claim 6, wherein said analgesic is an NSAID.
11. (Currently amended) The pharmaceutical composition of claim ~~40~~ 6, wherein said ~~NSAID~~ analgesic is selected from the group consisting of: acetaminophen; ibuprofen; flurbiprofen; ketoprofen; naproxen; oxaprozin; etodolac; indomethacin; ketorolac; nabumetane; piroxicam; celecoxib; rofecoxib; meloxicam; JTE-522; L-745,337; and NS398; or a pharmaceutically acceptable salt thereof.
12. (Currently amended) The pharmaceutical composition of claim 11, wherein said ~~NSAID~~ analgesic is naproxen.
13. (Previously presented) The pharmaceutical composition of claim 10, wherein said NSAID is long acting or is formulated to be long acting.
14. (Previously presented) A method of increasing the rate of absorption of a drug into the bloodstream of a patient, wherein rate of absorption is the time from which the drug is administered until the time that it reaches a peak plasma concentration, comprising:
administering said drug together with metoclopramide in a coordinated dosage form, wherein said metoclopramide is administered in an amount effective to increase gastric motility and wherein said drug is administered in a therapeutically effective amount.
15. (Previously presented) The method of claim 14, wherein said patient is in a state of gastric stasis at the time said drug and said metoclopramide are administered.
16. (Previously presented) The method of claim 14, wherein said drug is administered for the treatment of migraine headache.
17. (Previously presented) The method of claim 14, wherein said drug is an analgesic.

18. (Previously presented) The method of claim 14, wherein said drug is an NSAID.
19. (Previously presented) The method of claim 18, wherein said NSAID is long acting or is formulated to be long acting.
20. (Currently amended) The method of claim ~~18~~ 17, wherein said ~~NSAID~~ analgesic is selected from the group consisting of: acetaminophen; ibuprofen; flurbiprofen; ketoprofen; naproxen; oxaprozin; etodolac; indomethacin; ketorolac; nabumetane; piroxicam; celecoxib; rofecoxib; meloxicam; JTE-522; L-745,337; and NS398; or a pharmaceutically acceptable salt thereof.
21. (Currently amended) The method of claim 20, wherein said ~~NSAID~~ analgesic is naproxen.
22. (Previously presented) A pharmaceutical composition in unit dosage form suitable for oral administration in the treatment of migraine headache, comprising:
 - (a) metoclopramide in an amount effective to increase gastric motility in a patient; and
 - (b) a non-acidic analgesic in an amount effective to reduce or eliminate pain associated with said migraine headache;and wherein said unit dosage form is coordinated.
23. (Previously presented) The pharmaceutical composition of claim 22, wherein said unit dosage form is a tablet or capsule.
24. (Previously presented) The pharmaceutical composition of claim 22, wherein said unit dosage form is substantially free of any 5 HT agonist vasoactive agent.
25. (Previously presented) The pharmaceutical composition of claim 22, wherein said analgesic is a long acting NSAID.

26. (Previously presented) The pharmaceutical composition of claim 22, wherein said analgesic is a cyclooxygenase-2 inhibitor.
27. (Previously presented) The pharmaceutical composition of claim 26, wherein said cyclooxygenase-2 inhibitor is celecoxib.
28. (Previously presented) The pharmaceutical composition of claim 27, wherein said celecoxib is present in an amount of between 25 and 250 mg and said metoclopramide is present in an amount of between 1 mg and 100 mg.
29. (Previously presented) The pharmaceutical composition of claim 22, wherein said analgesic is formulated to be long acting.
- 30-33. Cancelled
34. (Currently amended) A pharmaceutical composition in unit dosage form suitable for oral administration to a human for the treatment of migraine headache, comprising: metoclopramide and an acidic analgesic, present in an amount such that the combination is effective in reducing or eliminating pain associated with said migraine headache and wherein said dosage form is ~~an acid-base storage stabilized dosage form in which said metoclopramide and said analgesic are each in separate layers of a multilayer tablet~~ due to either:
- a) a barrier coating separating said metoclopramide from said analgesic; or
- b) said analgesic and said metoclopramide being segregated into separate layers of a multilayer dosage form.
35. (Currently amended) ~~A The pharmaceutical composition in unit dosage form suitable for oral administration to a human for the treatment of migraine headache, comprising: metoclopramide and an analgesic, present in an amount such that the combination is effective in reducing or eliminating pain associated with said migraine headache, wherein~~

~~said dosage form is an acid-base storage stabilized dosage form and~~ of claim 34, wherein said unit dosage form is coordinated.

36. (Previously presented) The pharmaceutical composition of either claim 34 or 35, wherein either said metoclopramide or said analgesic is barrier coated.
37. (Previously presented) The pharmaceutical composition of either claim 34 or 35, wherein said unit dosage form is substantially free of any 5 HT agonist vasoactive agent.
38. (Previously presented) The pharmaceutical composition of either claim 34 or 35, wherein said analgesic is an NSAID.
39. (Currently amended) The pharmaceutical composition of ~~claim 38~~ either claim 34 or 35, wherein said ~~NSAID~~ analgesic is selected from the group consisting of: acetaminophen; ibuprofen; flurbiprofen; ketoprofen; naproxen; oxaprozin; etodolac; indomethacin; ketorolac; nabumetane; piroxicam; celecoxib; rofecoxib; meloxicam; JTE-522; L-745,337; and NS398; or a pharmaceutically acceptable salt thereof.
40. (Currently amended) The pharmaceutical composition of claim 39, wherein said ~~NSAID~~ analgesic is naproxen.
41. (Previously presented) The pharmaceutical composition of claim 38, wherein said NSAID is long acting or is formulated to be long acting.